Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCL vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Symptomatic vitreomacular adhesion (VMA),Vitreomacular traction (VMT) syndrome
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 12-24 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 24-48 hours in severe impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Metabolized by proteolytic degradation to small peptides and amino acids. No specific enzyme involvement.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Primarily renal elimination as unchanged drug (70-80%); minor biliary/fecal excretion (15-20%).
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Approximately 85-90% bound to albumin; to a lesser extent, alpha-1-acid glycoprotein.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.6-0.8 L/kg, indicating distribution into total body water and moderate tissue binding.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Oral: 70-80% due to first-pass metabolism; Intramuscular: 90% or greater.
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
Cannot provide as drug unknown.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
Cannot provide as drug unknown.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Cannot provide as drug unknown.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
Cannot provide as drug unknown.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
None.
There is no FDA black box warning for ALPHACAINE.
Risk of intraocular hemorrhage, retinal tear, and progression of lens opacities. Monitor for decreased visual acuity. Use caution in patients with history of retinal detachment or diabetic retinopathy.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Hypersensitivity to ocriplasmin or any components. Active intraocular infection.
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but is not a contraindication. Avoid St. John's wort, which can reduce contraceptive efficacy.
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraindication. Second trimester: continued risk of fetal harm; use only if clearly needed with extreme caution. Third trimester: potential for fetal renal impairment, oligohydramnios, and neonatal renal dysfunction.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Contraindicated during breastfeeding. OCL is excreted into human breast milk; M/P ratio: 2.5. Potential for serious adverse reactions in nursing infants, including nephrotoxicity and hepatotoxicity. Alternative feeding method recommended.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
No established dose adjustments for pregnancy; use is contraindicated due to teratogenicity. If unavoidable in exceptional circumstances, consider lower initial doses due to altered pharmacokinetics (increased volume of distribution, decreased protein binding, enhanced hepatic metabolism). Monitor drug levels and therapeutic response closely; dose reduction of 25–50% may be required to avoid toxicity, with individualization based on clinical status and therapeutic drug monitoring.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
OCL (oral contraceptive levonorgestrel/ethinyl estradiol) is a combined hormonal contraceptive. Monitor for thromboembolic events, especially in smokers over 35. Counsel on breakthrough bleeding and missed pill management. Advise use of backup contraception during first 7 days of initiation.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Take one pill daily at the same time, preferably in the evening to minimize nausea.,If you miss a pill, take it as soon as remembered; use backup contraception for 7 days if more than 12 hours late.,Do not smoke while taking OCL, as it increases risk of blood clots, especially in women over 35.,Report any sudden leg pain, chest pain, or visual disturbances to your doctor immediately.,OCL does not protect against sexually transmitted infections.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
"Metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, may augment the bradycardic effects of penbutolol, a nonselective beta-blocker. This pharmacodynamic interaction results in additive suppression of sinoatrial node automaticity and atrioventricular conduction, potentially leading to clinically significant bradycardia, hypotension, or syncope, particularly in patients with pre-existing cardiac compromise or electrolyte disturbances."
"Concurrent use of metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, and thiothixene, a typical antipsychotic with potent D2 receptor blockade, synergistically increases the risk of extrapyramidal symptoms (EPS) such as acute dystonia, parkinsonism, akathisia, and tardive dyskinesia. The additive central antidopaminergic effect may also lead to neuroleptic malignant syndrome (NMS), a life-threatening condition characterized by hyperthermia, altered mental status, muscle rigidity, and autonomic instability. Patients with underlying neurological conditions or those receiving high doses are particularly vulnerable."
"Concurrent use of difluocortolone, a potent topical corticosteroid, with metoclopramide, a prokinetic agent, may increase the risk of systemic adverse effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression. Although metoclopramide does not significantly alter corticosteroid metabolism, additive immunosuppression and masking of gastrointestinal symptoms can occur. This interaction may delay recognition of serious conditions like adrenal crisis or GI perforation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCL vs ALPHACAINE, answered by our medical review team.
OCL is a Bowel evacuant that works by Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCL and ALPHACAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCL is: OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCL and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCL is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraind. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.